Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial

The Lancet Oncology

Volumn 16, Issue 9, 2015, Pages 1049-1060

  Henderson, Michael A ^a   Burmeister, Bryan H ^d   Ainslie, Jill ^c   Fisher, Richard ^b   Di Iulio, Juliana ^b   Smithers, B Mark ^d   Hong, Angela ^e   Shannon, Kerwin ^e   Scolyer, Richard A ^e   Carruthers, Scott ^f   Coventry, Brendon J ^f   Babington, Scott ^g   Duprat, Joao ^h   Hoekstra, Harald J ⁱ   Thompson, John F ^e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Centre for Biostatistics and Clinical Trials   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF ADELAIDE   (Australia)

^g CHRISTCHURCH HOSPITAL   (New Zealand)

^h Estado de São Paulo Octavio Frias de Oliveira   (Brazil)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAZIL; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CLINICAL EFFECTIVENESS; FIBROSIS; HIGH RISK PATIENT; HUMAN; INFANT; LYMPH NODE DISSECTION; LYMPHEDEMA; MALE; MELANOMA; NERVE INJURY; NETHERLANDS; NEW ZEALAND; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION RESPONSE; RADIOTHERAPY EQUIPMENT; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; SUBCUTANEOUS TISSUE FIBROSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ADJUVANT THERAPY; AGED; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; KAPLAN MEIER METHOD; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; RECURRENCE;

EID: 84940590376     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00187-4     Document Type: Article

References (28)

1. Calabro A, Singletary SE, Balch CM Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989, 124:1051-1055.
2. Gadd MA, Coit DG Recurrence patterns and outcome in 1019 patients undergoing axillary or inguinal lymphadenectomy for melanoma. Arch Surg 1992, 127:1412-1416.
3. Agrawal S, Kane JM, Guadagnolo BA, Kraybill WG, Ballo MT The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 2009, 115:5836-5844.
4. Ballo MT, Bonnen MD, Garden AS, et al. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer 2003, 97:1789-1796.
5. Ballo MT, Ross MI, Cormier JN, et al. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys 2006, 64:106-113.
6. Ballo MT, Strom EA, Zagars GK, et al. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2002, 52:964-972.
7. Ballo MT, Zagars GK, Gershenwald JE, et al. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol 2004, 11:1079-1084.
8. Bibault JE, Dewas S, Mirabel X, et al. Adjuvant radiation therapy in metastatic lymph nodes from melanoma. Radiat Oncol 2011, 6:12.
9. Conill C, Valduvieco I, Domingo-Domenech J, Arguis P, Vidal-Sicart S, Vilalta A Loco-regional control after postoperative radiotherapy for patients with regional nodal metastases from melanoma. Clin Translal Oncol 2009, 11:688-693.
10. Strojan P, Jancar B, Cemazar M, Perme MP, Hocevar M Melanoma metastases to the neck nodes: role of adjuvant irradiation. Int J Radiat Oncol Biol Phys 2010, 77:1039-1045.
11. Shen P, Wanek LA, Morton DL Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanomas?. Ann Surg Oncol 2000, 7:554-559.
12. Creagan ET, Cupps RE, Ivins JC, et al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomised, prospective study. Cancer 1978, 42:2206-2210.
13. Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012, 13:589-597.
14. Burmeister BH, Mark Smithers B, Burmeister E, et al. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma: Trans Tasman Radiation Oncology Group (TROG) study 96.06. Radiother Oncol 2006, 81:136-142.
15. Burmeister BH, Smithers BM, Davis S, et al. Radiation therapy following nodal surgery for melanoma: an analysis of late toxicity. ANZ J Surg 2002, 72:344-348.
16. Cox JD, Stetz J, Pajak TF Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995, 31:1341-1346.
17. Common Terminology Criteria for Adverse Events version 2 (accessed Jan 31, 2015). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf.
18. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993, 11:570-579.
19. Core TR R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria (accessed Jan 31, 2015). http://www.R-project.org/.
20. Miller EJ, Daly JM, Synnestvedt M, Schultz D, Elder D, Guerry D Loco-regional nodal relapse in melanoma. Surg Oncol 1992, 1:333-340.
21. Beadle BM, Guadagnolo BA, Ballo MT, et al. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2009, 73:1376-1382.
22. Hamming-Vrieze O, Balm AJ, Heemsbergen WD, Hooft van Huysduynen T, Rasch CR Regional control of melanoma neck node metastasis after selective neck dissection with or without adjuvant radiotherapy. Arch Otolaryngol Head Neck Surg 2009, 135:795-800.
23. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
24. Bastiaannet E, Beukema JC, Hoekstra HJ Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications. Cancer Treat Rev 2005, 31:18-26.
25. Guadagnolo BA, Zagars GK Adjuvant radiation therapy for high-risk nodal metastases from cutaneous melanoma. Lancet Oncol 2009, 10:409-416.
26. Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev 2013, 6. CD008955.
27. Gyorki DE, Spillane J, Speakman D, Shackleton M, Henderson MA Current management of advanced melanoma: a transformed landscape. ANZ J Surg 2014, 84:612-617.
28. Eggermont AM, Chiarion-Sileni V, Grob J, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised double blind phase 3 trial. Lancet Oncol 2015, 16:522-530.